Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

The effects of forodesine in murine and human multiple myeloma cells.

Bieghs L, Caers J, De Bruyne E, Van Valckenborgh E, Higginbotham F, Vanderkerken K, Menu E.

Adv Hematol. 2010;2010:131895. doi: 10.1155/2010/131895.

2.

Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.

Balakrishnan K, Nimmanapalli R, Ravandi F, Keating MJ, Gandhi V.

Blood. 2006 Oct 1;108(7):2392-8.

3.

Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.

Alonso R, López-Guerra M, Upshaw R, Bantia S, Smal C, Bontemps F, Manz C, Mehrling T, Villamor N, Campo E, Montserrat E, Colomer D.

Blood. 2009 Aug 20;114(8):1563-75. doi: 10.1182/blood-2009-02-207654.

4.

Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.

Balakrishnan K, Ravandi F, Bantia S, Franklin A, Gandhi V.

Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):458-66. doi: 10.1016/j.clml.2013.04.009.

5.

Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.

Balakrishnan K, Burger JA, Quiroga MP, Henneberg M, Ayres ML, Wierda WG, Gandhi V.

Blood. 2010 Aug 19;116(7):1083-91. doi: 10.1182/blood-2009-10-246199.

6.
7.

Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).

Dummer R, Duvic M, Scarisbrick J, Olsen EA, Rozati S, Eggmann N, Goldinger SM, Hutchinson K, Geskin L, Illidge TM, Giuliano E, Elder J, Kim YH.

Ann Oncol. 2014 Sep;25(9):1807-12. doi: 10.1093/annonc/mdu231.

PMID:
24948692
8.

Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia.

Balakrishnan K, Verma D, O'Brien S, Kilpatrick JM, Chen Y, Tyler BF, Bickel S, Bantia S, Keating MJ, Kantarjian H, Gandhi V, Ravandi F.

Blood. 2010 Aug 12;116(6):886-92. doi: 10.1182/blood-2010-02-272039.

9.

Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.

Korycka A, Błoński JZ, Robak T.

Mini Rev Med Chem. 2007 Sep;7(9):976-83. Review.

PMID:
17897085
10.

A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).

Gandhi V, Kilpatrick JM, Plunkett W, Ayres M, Harman L, Du M, Bantia S, Davisson J, Wierda WG, Faderl S, Kantarjian H, Thomas D.

Blood. 2005 Dec 15;106(13):4253-60.

11.

Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.

Robak T, Lech-Maranda E, Korycka A, Robak E.

Curr Med Chem. 2006;13(26):3165-89.

PMID:
17168705
12.
13.

Older and new purine nucleoside analogs for patients with acute leukemias.

Robak P, Robak T.

Cancer Treat Rev. 2013 Dec;39(8):851-61. doi: 10.1016/j.ctrv.2013.03.006. Review.

PMID:
23566572
14.

In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.

Homminga I, Zwaan CM, Manz CY, Parker C, Bantia S, Smits WK, Higginbotham F, Pieters R, Meijerink JP.

Blood. 2011 Aug 25;118(8):2184-90. doi: 10.1182/blood-2011-02-337840.

15.
16.

A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.

Menu E, Garcia J, Huang X, Di Liberto M, Toogood PL, Chen I, Vanderkerken K, Chen-Kiang S.

Cancer Res. 2008 Jul 15;68(14):5519-23. doi: 10.1158/0008-5472.CAN-07-6404.

17.

Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.

Zhu K, Gerbino E, Beaupre DM, Mackley PA, Muro-Cacho C, Beam C, Hamilton AD, Lichtenheld MG, Kerr WG, Dalton W, Alsina M, Sebti SM.

Blood. 2005 Jun 15;105(12):4759-66.

18.

Forodesine treatment and post-transplant graft-versus-host disease in two patients with acute leukemia: facilitation of graft-versus-leukemia effect?

Gore L, Stelljes M, Quinones R.

Semin Oncol. 2007 Dec;34(6 Suppl 5):S35-9. Erratum in: Semin Oncol. 2008 Feb;35(1):92. Stelljes, Mattias [corrected to Stelljes, Matthias].

PMID:
18086346
19.

Matrine induces apoptosis of human multiple myeloma cells via activation of the mitochondrial pathway.

Han Y, Zhang S, Wu J, Yu K, Zhang Y, Yin L, Bi L.

Leuk Lymphoma. 2010 Jul;51(7):1337-46. doi: 10.3109/10428194.2010.488708.

PMID:
20528251
20.

Pharmacology and mechanism of action of forodesine, a T-cell targeted agent.

Gandhi V, Balakrishnan K.

Semin Oncol. 2007 Dec;34(6 Suppl 5):S8-12. Review.

PMID:
18086347
Items per page

Supplemental Content

Support Center